The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMW 2021 | Talquetamab, cevostamab and CAR-T in the future treatment of myeloma
Luciano Costa, MD, PhD, of the University of Alabama at Birmingham, Birmingham, AL, outlines how the latest drug therapies can be integrated into the treatment algorithm for multiple myeloma. Dr Costa also explains the excitement surrounding chimeric antigen receptor (CAR) T-cell therapies, such as idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), and bispecific antibodies, such as talquetamab and cevostamab, for the treatment of myeloma. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.
